Health Care & Life Sciences » Biotechnology | Orexigen Therapeutics Inc.

Orexigen Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2012
2013
2014
2015
2016
Net Income before Extraordinaries
90,094.00
77,671.00
37,525.00
68,687.00
24,524.00
Depreciation, Depletion & Amortization
313.00
94.00
139.00
223.00
3,735.00
Other Funds
8,112.00
8,584.00
19,967.00
20,464.00
100,884.00
Funds from Operations
81,669.00
68,993.00
17,419.00
48,000.00
121,673.00
Changes in Working Capital
13,327.00
1,824.00
44,247.00
6,473.00
11,960.00
Net Operating Cash Flow
68,342.00
70,817.00
26,828.00
54,473.00
109,713.00
Capital Expenditures
-
640.00
246.00
538.00
330.00
Purchase/Sale of Investments
13,345.00
20,636.00
23,194.00
41,960.00
43,223.00
Net Investing Cash Flow
13,345.00
21,276.00
23,440.00
41,422.00
107,057.00
Issuance/Reduction of Debt, Net
-
110,545.00
-
-
110,026.00
Net Financing Cash Flow
58,270.00
111,882.00
2,734.00
64,259.00
154,557.00
Net Change in Cash
23,417.00
19,789.00
6,122.00
51,179.00
62,928.00
Free Cash Flow
68,342.00
71,457.00
26,582.00
55,011.00
110,043.00
Net Assets from Acquisitions
-
-
-
-
63,504.00
Change in Capital Stock
58,270.00
1,337.00
2,734.00
64,259.00
44,531.00
Exchange Rate Effect
-
-
-
29.00
715.00

About Orexigen Therapeutics

View Profile
Address
3344 North Torrey Pines Court
La Jolla California 92037
United States
Employees -
Website http://www.orexigen.com
Updated 09/14/2018
Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities includes recruiting personnel, conducting research and development, including clinical trials, raising capital and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.